
    
      The duration of the study for an individual patient will include:

        -  The screening period = up to 4 weeks prior to the first administration of SAR3419.

        -  The treatment period:

             -  Induction period = 4 to 8 weeks

             -  Maintenance = up to a total maintenance treatment of 6 months

             -  A safety follow-up period of 42 days after the last dose.

        -  Any patient who discontinues the study treatment without disease progression will be
           followed every 2 months until disease progression, initiation of a new anti-cancer
           therapy, death or end-of-study date, whatever comes first.
    
  